FDA approves camizestrant for ESR1-mutated advanced breast cancer, tasking oncology nurses with guiding patients through ctDNA-based surveillance.
|Articles|July 28, 2015
Dr. Sara M. Tolaney on Neoadjuvant Treatment Considerations for TNBC
Author(s)Sara M. Tolaney, MD, MPH
Sara M. Tolaney, MD, MPH, medical oncologist, Dana-Farber Cancer Institute, discusses neoadjuvant treatment considerations for patients with triple-negative breast cancer (TNBC).
Advertisement
Sara M. Tolaney, MD, MPH, medical oncologist, Dana-Farber Cancer Institute, discusses neoadjuvant treatment considerations for patients with triple-negative breast cancer (TNBC).
Advertisement
Related to this article
Oncology clinicians must actively champion NCCN guidelines as a critical pillar of breast cancer survivorship care,
A nurse-led support program significantly reduces death anxiety in women with breast cancer on hormonal therapy, study finds.
FDA approves imlunestrant plus abemaciclib for ESR1-mutated, ER-positive, HER2-negative advanced or metastatic breast cancer after endocrine therapy.
Patients often use AI to read test results, but AI can misinterpret data and cause panic. Learn why human context remains critical.
Co-developed by NYU Langone and Dana-Farber, the Solavia platform integrates EHR workflows, decision support, and pathway tracking for APPs and PAs.
The FDA expands accelerated approval for sevabertinib to frontline HER2-mutant NSCLC, highlighting a need for vigilant nursing management of diarrhea.
Oncology nursing teams must navigate the clinical logistics and patient education for the newly approved, ctDNA-guided agent camizestrant.
Advertisement
Advertisement
Trending on Oncology Nursing News
1
Palliative and Psycho-Oncology Care: Dr. Ramy Sedhom on Patient Distress Signs
2
Psycho-Oncology Care: Dr. Erik Bengtsen on Psilocybin & Patient Distress
3
Nurse-Led Support Reduces Death Anxiety in Breast Cancer Care
4
Gynecologic Cancer Awareness: Dr. Teplinsky Discusses Nursing Roles
5